中国实验血液学杂志最新文献

{"title":"[Investigation on HTLV Infection among Voluntary Blood Donors in Fuzhou Area].","authors":"Ting-Ling Xue, Xiao-Zhen Zhou, Ai Zhang, Juan Liang, Wei-Mei Jiang, Shou Lin","doi":"10.19746/j.cnki.issn1009-2137.2026.04.026","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.026","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the infection status of human T-cell leukemia virus (HTLV) among voluntary blood donors in Fuzhou, and provide laboratory data support for formulating prevention and control strategies for HTLV-Ⅰ/Ⅱ in Fujian province.</p><p><strong>Methods: </strong>From August 1, 2016, to August 31, 2024, 386 740 voluntary blood donors in Fuzhou were initially screened for HTLV-Ⅰ/Ⅱ antibodies using enzyme-linked immunosorbent assay. Reactive specimens from the initial screening were confirmed using Western blot testing.</p><p><strong>Results: </strong>A total of 175 blood donors were confirmed to have HTLV-Ⅰ/Ⅱ antibody-positive results, with a confirmed positive rate of 0.045% (175/386 740). Pingtan Comprehensive Experimental Zone had the highest confirmed positive rate (0.262%, 33/12 604), while Taijiang District had the lowest (0.024%, 2/8 411). The difference in positive rate among regions was statistically significant (<i>P</i> <0.001). The 40-46 age group had the highest confirmed positive rate (0.104%, 48/45 984), and the difference was statistically significant among different age groups (<i>P</i> <0.001). The highest HTLV-Ⅰ/Ⅱ prevalence rate was observed in 2016 (0.049%, 17/34 353), while the lowest rate was observed in 2019 (0.018%, 14/76 018) and 2020 (0.018%, 13/73 128). The difference in prevalence rates among different years was statistically significant (<i>P</i> <0.001). In terms of gender, the confirmed positive rate was 0.044% (100/226 104) among males and 0.047% (75/160 636) among females, with no statistically significant difference (<i>P</i> >0.05).</p><p><strong>Conclusion: </strong>Fuzhou is a moderate prevalence area for HTLV-Ⅰ/Ⅱ, with prevalence rates varying by region, year, and age. Therefore, during blood donation recruitment, it is essential to implement targeted screening for high-risk groups to reduce the risk of HTLV-Ⅰ/Ⅱ transmission.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1114-1120"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070234","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Mechanism of Apoptosis for Corynoline-Mediated Reversing the Drug Resistance of AML HL-60/ADR Cells].","authors":"Shan Huang, Xing Wang, Lan-Yu Chen, Bo Ke, Mei Wu, Li Hou, Xin-Yi Chen, Zhi Zheng","doi":"10.19746/j.cnki.issn1009-2137.2026.04.008","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.008","url":null,"abstract":"<p><strong>Objective: </strong>To explore the function and molecular mechanism of corynoline in reversing drug resistance in acute myeloid leukemia cell line HL-60/adriamycin (ADR).</p><p><strong>Methods: </strong>HL-60/ADR cells were divided into four groups: control group, ADR group, corynoline group, and ADR+corynoline group. CCK-8 assay was applied to measure the cell viability and drug half maximal inhibitory concentration (IC₅₀), and flow cytometry was used to detect the intensity of intracellular ADR autofluorescence. Transcriptome sequencing was performed to explore its molecular mechanism, and RT-qPCR and Western blot were used to verify the expression of related genes, such as anti-apoptotic gene <i>BCL2</i> , pro-apoptotic gene <i>BAX</i> and drug-resistant gene <i>MRP1</i> . The expression of pathway related proteins enriched by differentially expressed genes was detected by Western blot.</p><p><strong>Results: </strong>Corynoline inhibited the viability of HL-60/ADR cells in a concentration- and time-dependent manner (<i>r</i> =-0.994, -0.981, -0.928). Compared with the ADR group, the ADR autofluorescence in HL-60/ADR cells was significantly enhanced in the ADR+corynoline group. The IC₅₀ in the ADR+corynoline group was 1.150 µmol/L, which was markedly decreased than 8.081 µmol/L in the ADR group. In contrast to the ADR group, the expression of p-AKT was down-regulated and the activity of PI3K/AKT signaling pathway was inhibited in the dual-drug combination group. Moreover, the expression of pro-apoptotic protein BAX was increased, while the expression of anti-apoptotic protein Bcl-2 and drug-resistant protein MRP1 was decreased.</p><p><strong>Conclusion: </strong>Corynoline has the function of reversing the drug resistance of HL-60/ADR cells, which is related to reducing the expression of intracellular drug resistance protein MRP1. Additionally, corynoline inhibits the activity of the PI3K/AKT signaling pathway in HL-60/ADR cells.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"986-992"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070296","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Establishment of a High-Viability Isolation, Identification, and Short-Term Culture System for Human Primary Acute Myeloid Leukemia Cells].","authors":"Jia-Xin Lyu, Tian-Jian Qiu, Pei Pei, Kang-Qi Lyu, Lin Li, Zheng-Yang Zhang, Jun-Jun Bai, Yi Zhang, Qing-Lin Song","doi":"10.19746/j.cnki.issn1009-2137.2026.04.041","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.041","url":null,"abstract":"<p><strong>Objective: </strong>To establish and optimize a protocol for the efficient isolation, identification, and short-term culture of primary CD34⁺ acute myeloid leukemia (AML) cells from bone marrow (BM) and peripheral blood (PB) samples of newly diagnosed AML patients, providing a stable primary cell model for basic and translational research on AML.</p><p><strong>Methods: </strong>BM and PB samples were collected from 10 newly diagnosed AML patients. Cells were enriched using Ficoll density gradient centrifugation combined with CD34⁺ immunomagnetic bead sorting. Sorting efficiency was evaluated by flow cytometry via CD34⁺/CD117⁺ immunophenotyping, and cell morphology was observed using Wright-Giemsa staining. Cell counts and CCK-8 assays were employed to dynamically monitor the proliferation and viability of BM- and PB-derived cells over 72 hours. Furthermore, the effects of 10% versus 20% fetal bovine serum (FBS) concentrations on the proliferation of BM-derived cells were compared.</p><p><strong>Results: </strong>Following immunomagnetic sorting, the purity of CD34⁺ cells from both BM and PB exceeded 90% (92.7%±2.7% for BM, 91.1%±3.0% for PB, <i>P</i>>0.05), with a high proportion of CD117⁺ co-expression (71.9%±3.3% for BM, 72.6%±3.0% for PB, <i>P</i>>0.05). The cells exhibited typical primitive myeloid morphology. During the 72-hour culture period, the peak proliferation at 48 hour (approximately 4.0×10³±0.2×10³ viable cells) and metabolic activity (OD₄₅₀ value of 1.59±0.07) of BM-derived cells were significantly higher than those of PB-derived cells (3.2×10³±0.1×10³, 1.14±0.08, both <i>P</i><0.01), with superior morphological stability in later stages. No statistically significant difference was observed between 10% and 20% FBS regarding short-term cell proliferation, although 20% FBS showed a slight advantage in maintaining cell morphology.</p><p><strong>Conclusion: </strong>This study successfully established a stable and efficient system for the isolation and short-term culture of human primary CD34⁺ AML cells. This system is applicable to both BM and PB samples. The results demonstrate that BM-derived cells possess stronger <i>in vitro</i> proliferative capacity and that 10% FBS is sufficient for their short-term culture requirements.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1210-1216"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149069854","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Application and Prospect of Artificial Intelligence and 3D Histopathology in the Diagnosis of Lymphoma--Review].","authors":"Tian Yu, Zi-Bo Yang, Meng-Yao Kang, Li-Ting Chen","doi":"10.19746/j.cnki.issn1009-2137.2026.04.043","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.043","url":null,"abstract":"<p><p>The rapid and accurate diagnosis of lymphoma is essential for understanding its pathogenesis, progression, and treatment outcomes. Compared to traditional diagnostic methods, artificial intelligence (AI) demonstrates superior data processing efficiency, delivering precise and consistent results. Meanwhile, three-dimensional (3D) histopathology provides a more comprehensive and detailed perspective of the disease. Consequently, the application of AI and 3D histopathology in lymphoma diagnosis is increasingly prevalent, addressing several challenges in current clinical practice. These technologies mitigate limitations related to diagnostic techniques and sample collection, reducing diagnostic turnaround time, and enhance accuracy. This review highlights recent advancements in AI and 3D histopathology for lymphoma diagnosis, while also discusses the remaining limitations and challenges in their implementation.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1222-1225"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070146","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Alantolactone Inhibits AML Cell Proliferation by Enhancing Reactive Oxygen Species and Downregulating the PI3K/Akt Signaling Pathway].","authors":"Qing Li, Rong Yan, Meng-Nan Yang, Kang-Xi Zhou, Jing Tan, Jing Wang, Ke-Sheng Dai","doi":"10.19746/j.cnki.issn1009-2137.2026.04.001","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.001","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effects of alantolactone (AL) on the proliferation and apoptosis of acute myeloid leukemia (AML) cells and its underlying molecular mechanisms.</p><p><strong>Methods: </strong>AML cell lines SHI-1 and THP-1 were treated with various concentrations of AL. Cell proliferation capacity was assessed using CCK-8 assay, and cell cycle distribution and apoptosis rate were analyzed by flow cytometry. Intracellular reactive oxygen species (ROS) levels were measured using DCFH-DA fluorescent probe, while the mitochondrial membrane potential (MMP) was evaluated using tetramethylrhodamine ethyl ester (TMRE). Western blot analysis was performed to detect the expression of cell cycle regulatory proteins (CDK4, CDK6), apoptosis-related proteins (cleaved caspase-3, Bax, Bcl-XL, PARP), and proteins involved in the PI3K/Akt signaling pathway.</p><p><strong>Results: </strong>AL significantly inhibited the proliferation of SHI-1 and THP-1 cells in a concentration-dependent (<i>r</i> _SHI-1=-0.942 2, <i>r</i> _THP-1=-0.882 6) and time-dependent (<i>r</i> _SHI-1=-0.979 3, <i>r</i> _THP-1=-0.940 0) manner. Meanwhile, AL treatment significantly increased the proportion of cells in G₀/G₁ phase and apoptosis rate of both SHI-1 and THP-1 cells (<i>P</i> < 0.05), and downregulated the expression of CDK4 and CDK6 (<i>P</i> < 0.05). Additionally, AL significantly upregulated Bax protein expression, downregulated Bcl-XL protein expression, activated caspase-3 and cleaved PARP, thereby promoting cell apoptosis (all <i>P</i> < 0.05). Furthermore, AL treatment significantly elevated intracellular ROS levels and decreased MMP (<i>P</i> < 0.05). Further studies demonstrated that AL could induce programmed cell death in AML cells by inhibiting the activation of the PI3K/Akt signaling pathway.</p><p><strong>Conclusion: </strong>AL may exert anti-leukemic effects by suppressing AML cell proliferation and inducing apoptosis through multiple mechanisms, including inhibition of PI3K/Akt signaling pathway activation, modulation of Bcl-2 family protein expression, and induction of intracellular oxidative stress.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"931-940"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070159","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Circ-LAMP1 Promotes Malignant Progression of Acute Myeloid Leukemia Cells by Regulating the miR-194-5p/SALL4 Axis].","authors":"Yun-Long DU, Yan Zhang, Chan Zhang, De-Long Fu","doi":"10.19746/j.cnki.issn1009-2137.2026.04.006","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.006","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the effect of circular RNA LAMP1 (circ-LAMP1) on the malignant progression of acute myeloid leukemia (AML) cells by regulating the miR-194-5p/SALL4 axis.</p><p><strong>Methods: </strong>Bone marrow fluid samples were collected from patients with AML and patients with megaloblastic anemia (MA). Human bone marrow stromal cells HS-5 and AML cells HL-60 were cultured <i>in vitro</i>. Quantitative real-time PCR (qRT-PCR) was used to detect the expression levels of circ-LAMP1, miR-194-5p, and <i>SALL4</i> mRNA in bone marrow samples and cells. HL-60 cells were divided into the following groups: control, si-NC, si-LAMP1, si-LAMP1+anti-miR-NC, and si-LAMP1+anti-miR-194-5p. CCK-8 assay and colony formation assay were used to detect cell proliferation ability; Transwell assay was used to detect cell invasion ability; Flow cytometry was used to detect cell apoptosis; Western blot was utilized to measure the expression levels of SALL4 protein and apoptosis-related proteins (Bax and Bcl-2) in cells; Dual-luciferase assay was conducted to verify the targeting relationship between miR-194-5p and circ-LAMP1, as well as between miR-194-5p and SALL4.</p><p><strong>Results: </strong>In the bone marrow samples of AML patients and HL-60 cells, the expression levels of circ-LAMP1 and <i>SALL4</i> mRNA were significantly upregulated ( <i>P</i> < 0.05), while the level of miR-194-5p was significantly downregulated ( <i>P</i> < 0.05). After silencing circ-LAMP1 (si-LAMP1 group), the cell viability, colony formation ability, number of invasive cells, as well as the expression levels of circ-LAMP1, <i>SALL4</i> mRNA, SALL4 protein and Bcl-2 protein in HL-60 cells were significantly decreased ( <i>P</i> < 0.05); Meanwhile, the apoptosis rate, miR-194-5p expression level, and Bax protein expression level were significantly increased ( <i>P</i> < 0.05). Inhibition of miR-194-5p significantly reversed the aforementioned effects mediated by circ-LAMP1 silencing. Dual-luciferase assay confirmed that circ-LAMP1 can specifically bind to miR-194-5p, and miR-194-5p directly targets the 3'UTR of <i>SALL4</i> .</p><p><strong>Conclusion: </strong>Circ-LAMP1 may promote the proliferation and invasion of AML cells and inhibit cell apoptosis by regulating the miR-194-5p/SALL4 axis.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"971-978"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070187","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Observation of Donor-Derived NK Cell Infusion in the Prevention of Cytomegalovirus Infection after Haploidentical Hematopoietic Stem Cell Transplantation].","authors":"Xiao-Li Zheng, Li Ding, Dong-Mei Han, Jing Liu, Sheng Li, Hong-Min Yan, Heng-Xiang Wang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.039","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.039","url":null,"abstract":"<p><strong>Objective: </strong>To observe the safety and clinical efficacy of adoptive infusion of donor-derived natural killer (NK) cells in the prevention of cytomegalovirus (CMV) infection after haploidentical hematopoietic stem cell transplantation (haplo-HSCT).</p><p><strong>Methods: </strong>18 patients who underwent haplo-HSCT were enrolled and received donor-derived peripheral blood NK cell infusion on the day of transplantation. 18 patients who had undergone haplo-HSCT without NK cell infusion in our department were included as controls. Vital signs and acute cell therapy-related toxicities were monitored during infusion and within 48 hours after infusion. The incidence of CMV infection from neutrophil engraftment to 3 months post-transplantation, the rate of acute graft-versus-host disease (GVHD), and survival status were documented.</p><p><strong>Results: </strong>The dose of infused NK cells was (4.83±1.37)×10⁷ cells/kg. Weight gain was seen in one patient after infusion and recovered with diuretic treatment. Three patients developed mild liver dysfunction and improved after medication. No patient showed symptoms of fever, rash, or capillary leak syndrome. Among the 18 patients in the NK cell infusion group, 7(38.9%) tested positive for CMV, which was significantly lower than 14(77.8%) in the historical control group (<i>P</i><0.05). There was no statistically significant difference in the incidence of acute GVHD between the two groups. There were 4 deaths in the NK cell infusion group: 2 due to thrombotic microangiopathy, 1 due to hepatic veno-occlusive disease, and 1 due to leukemia relapse. Four patients died in the control group: 3 due to thrombotic microangiopathy, and 1 due to disease relapse.</p><p><strong>Conclusion: </strong>Co-infusion of donor-derived NK cells during haplo-HSCT is safe and well-tolerated and effectively decreases the incidence of post-transplant CMV infection, providing a novel strategy for CMV prophylaxis after transplantation.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1196-1200"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070253","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical and Prognostic Analysis of Adrenal Aggressive B-cell Lymphoma].","authors":"Yao-Xu Chen, Yu-Tong Chen, Qian Zhou, Jia Zhao, Zhuo Wang, You-Fan Feng, Hui-Chun Wang, Xiao-Qin Liang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.013","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.013","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinicopathological characteristics, treatment modalities, and prognosis of adrenal aggressive B-cell lymphoma.</p><p><strong>Methods: </strong>A retrospective analysis was performed on the clinical data of 6 patients diagnosed with adrenal aggressive B-cell lymphoma in the Gansu Provincial Hospital from January 2013 to December 2024. Clinical presentations, pathological features, treatment strategies, and prognosis of the patients were analyzed, with a focus on exploring contemporary treatment approaches.</p><p><strong>Results: </strong>Among the 6 cases, 3 cases were male, with a median age of 62 years old. Initial clinical symptoms were often non-specific, the common manifestations included anemia, fatigue, lumbosacral and abdominal pain. Imaging revealed unilateral or bilateral adrenal space-occupying lesions. Pathological examination demonstrated a diffuse pattern of large lymphoid cells, with tumor cells exhibiting immunoblastic or centroblastic morphology, moderate cytoplasm, and eosinophilic or clear staining. Immunohistochemistry confirmed the expression of B-cell markers (CD20/CD79a) in tumor cells. Bcl-2 and Bcl-6 showed positive expression in all 6 cases, while 1 patient showed c-MYC positive expression, and 1 patient was EBER positive. In all 6 cases, the Ki-67 proliferation index exceeded 80%. Based on these findings, 5 cases were diagnosed with diffuse large B-cell lymphoma, and 1 case with EBV ⁺ large B-cell lymphoma. Among the 6 cases, 5 cases were initially treated with the R-CHOP regimen and achieved partial remission. One case underwent autologous hematopoietic stem cell transplantation after initial therapy with R-CHOP regimen, achieving complete remission. Follow-up data were available for all patients, ranging from 1 to 63 months, with a median follow-up of 32 months. The overall prognosis for these patients was favorable.</p><p><strong>Conclusion: </strong>Adrenal aggressive B-cell lymphoma is a rare malignancy characterized by non-specific clinical presentations. Accurate diagnosis requires a comprehensive approach integrating pathological morphology, immunophenotyping, and molecular detection. Timely and standardized treatment significantly improves survival rate.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1018-1023"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070306","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Correlation Between Molecular Genetic Features and Clinical Prognosis in Pediatric Burkitt Lymphoma].","authors":"Jie Wang, Hao Xiong, Zhuo Wang, Ming Sun, Bin Wu, Sha Wu, Lan-Nan Zhang, Shan-Shan Qi, Li Yang, Wei Wang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.012","DOIUrl":"https://doi.org/10.19746/j.cnki.issn1009-2137.2026.04.012","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Objective: &lt;/strong&gt;To analyze the molecular genetic characteristics of Burkitt lymphoma (BL) in children and dynamically monitor changes in plasma circulating tumor DNA (ctDNA) levels, as well as to explore its correlation with clinical features and prognosis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;A retrospective analysis was conducted on the clinical and molecular genetic data of 41 newly diagnosed pediatric BL patients admitted to the Hematology and Oncology Center of Wuhan Children's Hospital, Tongji Medical College, Huazhong University of Science and Technology, from January 2017 to July 2024. To explore the use of next-generation sequencing (NGS) for dynamically monitoring plasma ctDNA levels during treatment to assess therapeutic efficacy.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Among the 41 patients, 30 were male and 11 were female, with a median age at diagnosis of 5(1-13) years. According to the International Pediatric Non-Hodgkin Lymphoma Staging System, 3, 20, and 18 patients were classified as stage Ⅱ, Ⅲ, and Ⅳ, respectively. The most frequently identified genetic alterations included &lt;i&gt;IGH-MYC&lt;/i&gt; fusion (51.2%), and mutations in &lt;i&gt;ID3&lt;/i&gt; (48.7%), &lt;i&gt;MYC&lt;/i&gt; (46.3%), and &lt;i&gt;TP53&lt;/i&gt; (41.4%). The prevalence of EBV infection was significantly lower in patients with &lt;i&gt;ID3&lt;/i&gt; mutations than in those without mutations (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). Patients with &lt;i&gt;MYC&lt;/i&gt; mutations had a higher incidence of bulky disease compared to those without mutations (&lt;i&gt;P&lt;/i&gt; &lt; 0.05). &lt;i&gt;CCND3&lt;/i&gt; and &lt;i&gt;SMARCA4&lt;/i&gt; mutations were associated with significantly elevated lactate dehydrogenase levels at initial diagnosis (both &lt;i&gt;P&lt;/i&gt; &lt; 0.05). All patients were treated with chemotherapy according to the CNCL-NHL-2017 regimen or BFM-95 regimens for mature B-cell NHL. The median follow-up time was 4.5(1.5-8.0) years. The expected 5-year overall survival (OS) rate was 86.6% (95%&lt;i&gt;CI&lt;/i&gt; : 70.6%-94.2%), and the 5-year relapse-free survival (RFS) rate was 85.1% (95%&lt;i&gt;CI&lt;/i&gt; : 68.6%-95.0%). No significant correlation was observed between genetic mutations and interim treatment response. Although patients with &lt;i&gt;TP53&lt;/i&gt; mutation had a lower OS rate than those without mutation, the difference was not statistically significant (&lt;i&gt;P&lt;/i&gt; &gt;0.05). Plasma ctDNA was successfully obtained from 19 patients. The mutational profile detected in ctDNA was highly consistent with that from tissue samples. Dynamic monitoring during treatment showed that ctDNA abundance dropped to zero by the mid-term assessment and at the end of treatment. All 19 children in this subgroup survived.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;BL patients harbor a characteristic genetic mutation profile, which correlates with certain clinical features but shows limited independent prognostic value in this cohort. Plasma ctDNA demonstrates high concordance with the mutation profile of tissue samples, and its dynamic changes reflect treatment response. However, its clinical utility requires validation in p","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1012-1017"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070273","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical Characteristics Analysis of Primary Gastric Large B-Cell Lymphoma with <i>IRF4</i> Rearrangement].","authors":"Chang-Ying Gu, He-Sheng He, Chen Huang, Jun-Ping Yao, Su-Fen Wang, Hua Jiang","doi":"10.19746/j.cnki.issn1009-2137.2026.04.011","DOIUrl":"10.19746/j.cnki.issn1009-2137.2026.04.011","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the clinical characteristics and diagnostic approaches for patients with primary gastric large B-cell lymphoma with <i>IRF4</i> rearrangements (LBCL-IRF4), thereby enhancing understanding of this distinct subtype.</p><p><strong>Methods: </strong>A retrospective analysis was conducted on the clinical presentation, diagnostic and therapeutic course, and prognosis of this single case of primary gastric LBCL-IRF4 treated in our hospital.</p><p><strong>Results: </strong>Based on pathological, imaging, and bone marrow examinations, the patient was diagnosed with LBCL-IRF4 (Stage ⅡA, IPI score: 1, low risk; NCCN-IPI score: 2, intermediate-low risk; CNS score: 1, low risk). The patient received four cycles of the R-CDOP regimen (rituximab + cyclophosphamide + vindersine + liposomal doxorubicin + prednisolone tablets) followed by two additional cycles of rituximab consolidation therapy. The patient achieved complete remission.</p><p><strong>Conclusion: </strong>LBCL-IRF4 is clinically uncommon, and primary gastric LBCL-IRF4 is even rare. Such patients demonstrate favourable outcomes following standard treatment.</p>","PeriodicalId":35777,"journal":{"name":"中国实验血液学杂志","volume":"34 4","pages":"1006-1011"},"PeriodicalIF":0.0,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149070250","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}